Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imidazoline receptors: a challenge.

P Bousquet1, V Bruban, S Schann

  • 1Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Faculté de Médecine, Université Louis Pasteur, Strasbourg, France. pascal.bousquet@medecine.u-strasbg.fr

Pharmaceutica Acta Helvetiae
|May 17, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining structural modeling and deep learning to calculate the E. coli protein interactome and functional networks.

Nature communications·2026
Same author

Why methane surged in the atmosphere during the early 2020s.

Science (New York, N.Y.)·2026
Same author

Combining structural modeling and deep learning to calculate the <i>E. coli</i> protein interactome and functional networks.

bioRxiv : the preprint server for biology·2025
Same author

Study of upright patient positioning reproducibility in image-guided proton therapy for head and neck cancers.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

Impact of an automated report comparison tool on trainee report modification rate at a tertiary hospital.

Clinical radiology·2024
Same author

Searching for clinical trials in oncology: finding a path through the maze.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same journal

Pressing and casting suppositories.

Pharmaceutica acta Helvetiae·2010
Same journal

Investigations on Kapaloin.

Pharmaceutica acta Helvetiae·2010
Same journal

Studies in the manufacture of pharmaceutical emulsions for internal use.

Pharmaceutica acta Helvetiae·2010
Same journal

To determine the value and manufacture of the Compressi Codeini compositi Ph.H.V.

Pharmaceutica acta Helvetiae·2010
Same journal

Sources of error in the bromometric titration of salicylic acid.

Pharmaceutica acta Helvetiae·2010
Same journal

Identity reactions of extracts containing anthraquinone in ultraviolet light.

Pharmaceutica acta Helvetiae·2010
See all related articles

Imidazoline drugs lower blood pressure by acting on imidazoline receptors (IRs) in the brainstem. Their full hypotensive effect requires both IRs and intact alpha-2-adrenoceptors (A2Rs).

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cardiovascular Research

Background:

  • Imidazoline-like drugs (IMs) administered to the brainstem's rostroventrolateral medulla (NRL/RVLM) induce hypotension.
  • The mechanism involves imidazoline-specific receptors (IRs), independent of alpha-adrenoceptor (A2R) affinity.
  • Recent development of highly IR-selective compounds offers new insights into their hypotensive potential.

Purpose of the Study:

  • To elucidate the precise roles of imidazoline receptors (IRs) and alpha-2-adrenoceptors (A2Rs) in the central hypotensive effects of imidazoline-like drugs.
  • To investigate whether high selectivity for IRs predicts hypotensive capability.
  • To determine the necessity of intact A2Rs for the full hypotensive response.

Main Methods:

  • Direct injection of imidazoline-like drugs and selective agonists/antagonists into the NRL/RVLM.

Related Experiment Videos

  • Assessment of blood pressure changes in response to various compounds with differing affinities for IRs and A2Rs.
  • Utilizing specific antagonists (idazoxan, yohimbine) and receptor mutation studies.

    • Main Results:

    • Highly IR-selective compounds can independently reduce blood pressure.
    • The central hypotensive effect of IMs requires IR activation and is enhanced by concurrent A2R activation.
    • Antagonism or mutation of A2Rs significantly impairs or abolishes the hypotensive effects of IMs and hybrid drugs.
    • No correlation exists between IM affinity for A2Rs and their central hypotensive effects.

    Conclusions:

    • Drugs highly selective for I1Rs over A2Rs can lower blood pressure via direct action.
    • The central hypotensive effect of IMs necessitates IR involvement and is facilitated by additional A2R activation.
    • Intact A2Rs are crucial for mediating the full hypotensive effect of centrally acting IMs along sympathetic pathways.